Can the new drug CX-5461 cure leukemia?
Important notice: You must inform your CML doctor or a qualified doctor before using this drug. The material presented here is for information purposes only; it is not a substitute for your physician’s guidance and care.
“RNA Polymerase I (Pol I) activity is essential for cancer cell survival. Scientists are discovering that its inhibition selectively activates p53 (tumor suppressor protein) to kill tumors. Cylene Pharmaceuticals, founded by Daniel Von Hoff the world's leading clinical oncologist, has found that the Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant cells but not in normal cells.….”
“Pol 1 is a true target for cancer. Even a modest reduction in Pol 1 selectively kills cancer cells but not normal cells and that was really a major finding to show that you can reduce Pol 1 in cancer cells and it kills them but it does not kill normal cells," Dr. Rice said.…”
''This drug will be clinically tried in human patients in just a couple of months. The Peter MacCallum Cancer Center in Melbourne Australia received a grant from the Australian Government to support this first-in-human trial."
Extract from New Drug Stunts Tumor Growth
“RNA Polymerase I (Pol I) activity is essential for cancer cell survival. Scientists are discovering that its inhibition selectively activates p53 (tumor suppressor protein) to kill tumors. Cylene Pharmaceuticals, founded by Daniel Von Hoff the world's leading clinical oncologist, has found that the Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant cells but not in normal cells.….”
“Pol 1 is a true target for cancer. Even a modest reduction in Pol 1 selectively kills cancer cells but not normal cells and that was really a major finding to show that you can reduce Pol 1 in cancer cells and it kills them but it does not kill normal cells," Dr. Rice said.…”
''This drug will be clinically tried in human patients in just a couple of months. The Peter MacCallum Cancer Center in Melbourne Australia received a grant from the Australian Government to support this first-in-human trial."
Extract from New Drug Stunts Tumor Growth
New breakthrough gives hope to cancer sufferers
July 10, 2012, ABC News
Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53
July 10, 2012, Cancer Cell
New blood cancer treatment to be tested
July 10, 2012, AdelaideNow
Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
July 10, 2012, Yahoo! Finance
Experimental drug activates key anti-cancer mechanism
July 10, 2012, Cancer Research UK
New Target Discovered Deep Within Cancer Cells
July 9, 2012, Science Daily
New Drug Stunts Tumor Growth
July 1, 2012, Ivanhoe
Cylene Pharma.- First-in-Class Agents Show Promise in High Risk Blood Cancers at ASH
December 13, 2011, Biospace.com
CX-5461. Non-Genotoxic Activator of p53 through Selective Inhibition of RNA Polymerase I for the Treatment of Hematologic Malignancies
July 1, 2011, CylenePharma
Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth
December 15, 2010, Cancer Research
July 10, 2012, ABC News
Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53
July 10, 2012, Cancer Cell
New blood cancer treatment to be tested
July 10, 2012, AdelaideNow
Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
July 10, 2012, Yahoo! Finance
Experimental drug activates key anti-cancer mechanism
July 10, 2012, Cancer Research UK
New Target Discovered Deep Within Cancer Cells
July 9, 2012, Science Daily
New Drug Stunts Tumor Growth
July 1, 2012, Ivanhoe
Cylene Pharma.- First-in-Class Agents Show Promise in High Risk Blood Cancers at ASH
December 13, 2011, Biospace.com
CX-5461. Non-Genotoxic Activator of p53 through Selective Inhibition of RNA Polymerase I for the Treatment of Hematologic Malignancies
July 1, 2011, CylenePharma
Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth
December 15, 2010, Cancer Research
